| Characteristic | Low expression of GGCT | High expression of GGCT | p |
| n | 532 | 533 |
|
| T stage, n (%) |
|
| 0.044 |
| T1 | 149 (14%) | 126 (11.9%) |
|
| T2 | 291 (27.4%) | 324 (30.5%) |
|
| T3 | 77 (7.3%) | 60 (5.6%) |
|
| T4 | 13 (1.2%) | 22 (2.1%) |
|
| N stage, n (%) |
|
| 0.477 |
| N0 | 257 (24.6%) | 250 (23.9%) |
|
| N1 | 179 (17.1%) | 170 (16.3%) |
|
| N2 | 51 (4.9%) | 65 (6.2%) |
|
| N3 | 34 (3.3%) | 40 (3.8%) |
|
| M stage, n (%) |
|
| 0.507 |
| M0 | 445 (49%) | 444 (48.8%) |
|
| M1 | 8 (0.9%) | 12 (1.3%) |
|
| Pathologic stage, n (%) |
|
| 0.473 |
| Stage I | 95 (9.1%) | 85 (8.2%) |
|
| Stage II | 305 (29.3%) | 301 (28.9%) |
|
| Stage III | 111 (10.7%) | 127 (12.2%) |
|
| Stage IV | 7 (0.7%) | 11 (1.1%) |
|
| Age, n (%) |
|
| 0.880 |
| ≤60 | 292 (27.4%) | 296 (27.8%) |
|
| >60 | 240 (22.5%) | 237 (22.3%) |
|
| Histological type, n (%) |
|
| <0.001 |
| Infiltrating Ductal Carcinoma | 341 (35.6%) | 416 (43.4%) |
|
| Infiltrating Lobular Carcinoma | 123 (12.8%) | 79 (8.2%) |
|
| PR status, n (%) |
|
| 0.007 |
| Negative | 147 (14.5%) | 191 (18.8%) |
|
| Indeterminate | 2 (0.2%) | 2 (0.2%) |
|
| Positive | 359 (35.3%) | 315 (31%) |
|
| ER status, n (%) |
|
| <0.001 |
| Negative | 91 (8.9%) | 146 (14.4%) |
|
| Indeterminate | 0 (0%) | 2 (0.2%) |
|
| Positive | 417 (41%) | 361 (35.5%) |
|
| HER2 status, n (%) |
|
| <0.001 |
| Negative | 311 (43.4%) | 237 (33.1%) |
|
| Indeterminate | 9 (1.3%) | 3 (0.4%) |
|
| Positive | 44 (6.1%) | 113 (15.8%) |
|